BeiGene Ltd. is a leading pharmaceutical company based in the Cayman Islands. With a Risk Rating Score of 22.7, the company is considered to be of medium risk. Specializing in oncology, BeiGene is focused on developing innovative and affordable treatments for cancer patients worldwide. Their key products include BRUKINSA, a BTK inhibitor, and TEVIMBRA, an anti-PD-1 antibody. BeiGene also has a diverse pipeline of therapeutics targeting various types of cancers. Operating in the pharmaceutical products segment, the company generates significant revenue in the U.S. and the PRC. Improve your ESG score with BeiGene Ltd.'s sustainable and governance-focused pharmaceutical solutions.